HIT Consultant November 13, 2024
Syed Hamza Sohail

What You Should Know:

Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.

– This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.

Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery

Genesis Therapeutics, an AI-focused biotechnology company headquartered in Burlingame, CA, is revolutionizing small molecule drug discovery through its proprietary generative and predictive AI platform, **GEMS (Genesis Exploration of Molecular Space)**. GEMS integrates cutting-edge AI methodologies, including language models, diffusion models, and physical machine learning (ML) simulations, to generate and optimize molecules targeting complex biological structures.

Key Highlights of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
Breaking Through The Generative AI Memory Wall
Google Cloud launches AI Agent Space amid rising competition
Navigating C-Suite Challenges: Budgeting With AI In Mind For 2025
Report: OpenAI Considers Adding Web Browser and Search Partnerships
How AI-Driven Recruitment Can Shape A More Equitable Future

Share This Article